NCT07092514
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07092514
Title Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Washington University School of Medicine
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.